Bill · H.R. 3375· House(119-HR-3375)
Fair Prescription Drug Prices for Americans Act
- Introduced
- 5/13/2025
- Last activity
- 5/13/2025 — Referred to the House Committee on Energy and Commerce.
- Sponsored by
- Jefferson Van Drew
- Cosponsors
- None
- Introduced
- In Committee
What this bill would do
This bill, known as the "Fair Prescription Drug Prices for Americans Act," seeks to cap the retail list price of certain prescription drugs and biological products. Under this Act, the price in the United States cannot exceed the average retail list price found in Canada, France, Germany, Italy, Japan, and the United Kingdom. The Secretary of Health and Human Services is responsible for calculating this annual average using manufacturer data and public records. Manufacturers are required to submit annual list price data for the United States and the specified foreign nations. To enforce this, the bill establishes civil monetary penalties for manufacturers that exceed the calculated price cap.
Yes· 3 of 7
Does this lower the price of prescription medicines?+8
The bill mandates that the retail list price of drugs and biological products cannot exceed the average price in several other nations.
Would households on low incomes be better off under this?+7
Lowering medication costs directly benefits those with limited financial resources.
Would people over 65 be better off under this?+6
Reducing drug prices provides significant financial relief to seniors who often rely on prescription medications.
The opposite
No question was scored the opposite.
Who it would affect, and how
Potential Positive Impacts for People
-
Price Caps on Medication: The retail list price for drugs and biological products in the United States will be capped so it cannot exceed the average price in Canada, France, Germany, Italy, Japan, and the United Kingdom. This is found in Section 2(b).
-
Enforcement through Penalties: Manufacturers that violate the price cap will be subject to a civil monetary penalty. This penalty is calculated by multiplying the difference between the U.S. list price and the international average by 10 for each unit sold. This is found in Section 2(d).
Potential Negative Impacts for People
- No negative impacts or burdens are explicitly stated in the provided text.
Groups and Interests Ranking
Every group the model scored this bill for, from -10 to +10. Hover a score for the reason it gave.
- Demographic And Interest Groups
- Good For Low Income Households+7Good For Seniors+6Good For Middle Class Households+5
- Healthcare
- Reduces Prescription Drug Costs+8Improves Healthcare Access+5
- Economy And Finance
- Improves Consumer Protection+6
- Social Issues And Justice
- Improves Poverty Reduction+3
- 5/13/2025
- Referred to the House Committee on Energy and Commerce.
- Introduced in House
One bill Congress.gov lists as related to this one — companions in the other chamber, earlier versions, and bills this one absorbed or was folded into.